Detalles de la búsqueda
1.
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
Blood
; 119(15): 3512-22, 2012 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-22368272
2.
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Pediatr Blood Cancer
; 57(4): 569-77, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21360654
3.
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Blood
; 111(12): 5477-85, 2008 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18388178
4.
Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
Cytometry B Clin Cytom
; 68(1): 18-24, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16184615
5.
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
Blood
; 109(3): 926-35, 2007 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17003380
Resultados
1 -
5
de 5
1
Próxima >
>>